| dc.description.sponsorship | This study was sponsored by Servier and Taiho Oncology, Inc. GWP has been an expert witness for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Hoffmann-La Roche, Merck KGaA, MSD, Novartis, Pierre Fabre, and Servier and has received consulting fees from Bayer. JT has received consulting fees from Amgen, Astellas, Bristol Myers Squibb, Merck, MSD, Novartis, Pierre Fabre, and Servier. MW has received consulting fees from Amgen, Array BioPharma, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Incyte, Mirati Therapeutics, Nouscom, PsiOxus Therapeutics, Taiho Oncology, Inc., and Xenthera. FC has received a research grant from Amgen, Bayer, AstraZeneca, Hoffmann-La Roche, and Merck KGaA and has received consulting fees from Bayer, Hoffmann-La Roche, Merck KGaA, Pfizer, Pierre Fabre, and Servier. EVC has received consulting fees from AbbVie, ALX Oncology, Amgen, Array BioPharma, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Hoffmann-La Roche, GlaxoSmithKline, Incyte, Ipsen, Merck, Mirati Therapeutics, Nordic Pharma, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, Servier, Taiho Pharmaceutical Co., Takeda Oncology, Terumo, and Zymeworks. EE has received speaker fees from Amgen, Merck, Organon, Pierre Fabre, Sanofi Aventis, and Servier and has received consulting fees from Bayer, Hoffmann-La Roche, and Novartis. GL has received consultancy fees from Danone and funding for an educational workshop from Servier. DPM has received honoraria for lectures from Amgen, AstraZeneca, Bristol Myers Squibb, Lilly Deutschland, Merck, Pierre Fabre., Seagen, Servier, and Taiho Pharmaceutical Co., consultancy fees from Amgen, Onkowissen, Pierre Fabre, and Takeda Oncology, grants from Amgen and Servier, funds toward travel from Amgen and Servier, and funding as a member of an endpoint review committee from Servier. JT has received consultancy fees from Array BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly and Company, Hoffmann-La Roche, Genentech, HalioDX SAS, Hutchinson MediPharma, Ikena Oncology, Inspirna, IQVIA, Menarini, Merck Serono, Merus, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, SOTIO Biotech, Taiho Pharmaceutical Co., Tessa Therapeutics, and TheraMyc, has received support for an educational collaboration from Imedex /HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education, and Physicians Education Resource (PER), and has stock in Oniria Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. |
| dc.contributor.authoraffiliation | [Prager GW] The Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. [Taieb J] The Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC Cancer Research for Personalized Medicine, Université Paris Cité, Paris, France. [Fakih M] City of Hope Comprehensive Cancer Center, Duarte, CA, USA. [Ciardiello F] Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. [Van Cutsem E] The Department of Digestive Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium. [Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. International Oncology Bureau-Quiron, Barcelona, Spain |
Àrea privada
Contacte
